title: Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: a retrospective study.
abstract: Quetiapine fumarate, a first-line treatment for schizophrenia, exists in two formulations: extended release (XR) and immediate release (IR). This naturalistic, noninterventional study evaluated use of quetiapine XR/IR among in-patients with schizophrenia [ClinicalTrials.gov identifier: NCT01214135]. Data were collected from medical records. Categorical and numerical outcomes were compared using χ(2) and t tests. Of 178 enrolled patients, 66% and 34% used quetiapine XR and IR respectively. Based on mean daily dose, XR was used as antipsychotic medication in 64% of patients compared with 40% of patients on IR (dose ≥ 400 mg/day; p = 0.002) and in higher doses than IR (494 versus 345 mg/day; p = 0.001; calculated averages). Schizophrenia was more commonly reported as reason for use of XR than IR (20% versus 0%; p = 0.0003). Patients with comorbid substance abuse or somatic disease were more likely to receive XR (p = 0.003; p = 0.03). Treatment cessation due to nonadherence was less common in patients on XR (3.4% versus 12%; p = 0.03). Polypharmacy was seen in 98% of patients. Quetiapine XR/IR usage varies in hospitalized patients with schizophrenia. XR is more often used in antipsychotic dosage; IR is more commonly used at lower doses as add-on therapy. Both quetiapine XR and IR have their place in clinical practice and provide treatment choice in schizophrenia.
authors: Sahlgrenska University Hospital, Lillhagsparken 3, Hisings-Backa, SE42250, Gothenburg, Sweden.
authors: Lars
authors: L
authors: Eriksson
authors: Teresa
authors: T
authors: Hallerbäck
authors: Leif
authors: L
authors: Jørgensen
authors: Andreas
authors: A
authors: Carlborg
keywords: Comorbidity; concomitant medication; in-patients; naturalistic study; quetiapine; schizophrenia
references: Hum Psychopharmacol. 2010 Mar;25(2):103-15
references: 20196185
references: Psychiatry Res. 2008 Nov 30;161(2):235-47
references: 18849080
references: Int J Neuropsychopharmacol. 2011 Nov;14(10):1357-66
references: 21477416
references: Dialogues Clin Neurosci. 2010;12(3):345-57
references: 20954430
references: Br J Psychiatry. 2006 Nov;189:433-40
references: 17077434
references: Schizophr Res. 2007 Feb;90(1-3):229-37
references: 17208414
references: Psychiatry (Edgmont). 2007 Nov;4(11):34-50
references: 20428302
references: Pharmacopsychiatry. 2010 Jun;43(4):122-9
references: 20309809
references: Arch Gen Psychiatry. 2000 Jun;57(6):553-9
references: 10839333
references: J Clin Psychiatry. 2008 Jan;69(1):81-6
references: 18312041
references: Ann Clin Psychiatry. 2008 Jan-Mar;20(1):15-20
references: 18297582
references: J Clin Psychiatry. 2011 Apr;72(4):e13
references: 21527119
references: BMJ. 1999 Aug 28;319(7209):562-4
references: 10463902
references: Schizophr Bull. 2010 Jan;36(1):94-103
references: 19955388
references: Acta Psychiatr Scand Suppl. 2006;(429):46-50
references: 16445482
references: J Clin Psychiatry. 2004 Mar;65(3):354-60
references: 15096075
references: Psychiatr Serv. 2003 Apr;54(4):508-16
references: 12663838
references: BMC Psychiatry. 2010 Mar 24;10:26
references: 20334680
references: BMC Psychiatry. 2010 Sep 28;10:75
references: 20920179
references: Schizophr Bull. 2009 Sep;35(5):931-6
references: 18385207
references: Neuropsychiatr Dis Treat. 2007 Apr;3(2):219-35
references: 19300555
references: Med J Aust. 2002 Oct 21;177(8):410-1
references: 12381248
references: Clin Ther. 2009 Mar;31(3):492-502
references: 19393840
references: CNS Drugs. 2011 May;25(5):383-99
references: 21476610
references: Psychiatr Serv. 2010 Apr;61(4):405-8
references: 20360281
references: CMAJ. 2005 Jun 21;172(13):1703-11
references: 15967975
references: Curr Med Res Opin. 2008 Aug;24(8):2271-82
references: 18588748
references: Nord J Psychiatry. 2003;57(4):263-9
references: 12888400
references: Eur Neuropsychopharmacol. 2006 Sep;16 Suppl 3:S156-62
references: 16872807
references: Expert Rev Neurother. 2010 Jul;10(7):1153-64
references: 20586695
references: Psychiatr Serv. 2003 Jan;54(1):55-9
references: 12509667
references: Curr Med Res Opin. 2010 Oct;26(10):2403-10
references: 20812791
references: BMC Psychiatry. 2009 May 16;9:24
references: 19445700
references: CNS Drugs. 2009;23(3):261-9
references: 19320534
references: Pharmacopsychiatry. 2010 Aug;43(6):221-4
references: 20503150
references: J Clin Psychiatry. 2006;67 Suppl 5:3-8
references: 16822090
references: Int J Neuropsychopharmacol. 2010 Aug;13(7):971-3
references: 20128954
references: CNS Drugs. 2009 Aug;23(8):649-59
references: 19594194
references: Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):199-204
references: 18948162
references: Pharm World Sci. 2007 Jun;29(3):126-30
references: 17333501
references: BMJ. 2000 Dec 2;321(7273):1371-6
references: 11099280